Compare Merck & Co., Inc. (MRK) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Rent the Runway Inc — how do they compare? Merck & Co., Inc. trades at $145.12 (market cap $351.28B), while Rent the Runway Inc trades at $1.76 (market cap $61.75M). The key difference: Merck & Co., Inc. is far larger — about 5688.7× Rent the Runway Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Rent the Runway Inc for 56 Days on average.
| MRK | RENT | |
|---|---|---|
Market Cap | $351.28B | $61.75M |
Volume | 7,969,665 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $9.39 |
52-Week Low | $82.49 | $1.55 |
Typical Hold Time | 98 Days | 56 Days |
Enterprise Value | $398.04B | $228.75M |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Rent the Runway (RENT) trades at $1.68, up 1.82% on the day, amid a bearish technical signal. The company reported revenue of $306.20M in 2025 with a net loss of $69.90M, though losses are narrowing year-over-year. Recent news includes a CEO appointment and multiple law firm investigations into investor claims, creating mixed sentiment.
The outlook is cautious; while revenue growth and margin improvements are positive, negative shareholder equity and high debt levels pose significant risks. Analyst consensus is mixed with 42% buy ratings, but legal overhangs and profitability challenges temper near-term optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
